Sapient Capital’s Intensity Therapeutics INTS Stock Holding History

Sapient Capital’s Portfolio INTS Stock Details INTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-26,006	Closed	-$107K	–	404
2026 Q2	$107K	Hold	26,006	–	–	﹤0.01%	390
2026 Q1	$153K	Hold	26,006	–	–	﹤0.01%	433
2025 Q4	$244K	Sell	26,006 -13,066	-33%	-$132K	﹤0.01%	377
2025 Q3	$240K	Hold	39,072	–	–	﹤0.01%	351
2025 Q2	$300K	Hold	39,072	–	–	0.01%	305
2025 Q1	$1.92M	Buy	39,072 +1,358	+4%	+$75.5K	0.04%	148
2024 Q4	$1.66M	Sell	37,714 -2,716	-7%	-$197K	0.03%	155
2024 Q3	$3.86M	Hold	40,430	–	–	0.08%	102
2024 Q2	$4.95M	Sell	40,430 -53	-0.1%	-$6.01K	0.1%	93
2024 Q1	$5.26M	Buy	40,483 +32,483	+406%	+$3.89M	0.12%	99
2023 Q4	$1.71M	Buy	+8,000	New	+$842K	0.04%	132

Other funds holding INTS

Kingsbury Capital Investment Advisors Wilmette, Illinois $106M AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Sapient Capital's INTS Position: Q3 2026 in Review

Sapient Capital sold out of Intensity Therapeutics (INTS) in Q3 2026, closing a stake of 26,006 shares — an estimated $107K sold.

Sapient Capital first reported a position in INTS in Q4 2023 and held it in 11 quarters. The position peaked at $5.26M in Q1 2024. 8 funds tracked by Wall St. Rank hold INTS as of Q3 2026.

Sapient Capital reported no remaining Intensity Therapeutics position as of Q3 2026 after selling out during the quarter.
Sapient Capital sold 26,006 Intensity Therapeutics shares in Q3 2026, an estimated $107K.
Sapient Capital first reported a position in Intensity Therapeutics in Q4 2023 and held it in 11 quarters.
Sapient Capital's Intensity Therapeutics position peaked at $5.26M in Q1 2024.
8 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2026.

Based on Sapient Capital's 13F filing for Q3 2026, filed 8 Oct 2026.